- Home
- HALO
as 07-04-2025 11:35am EST
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 7.4B | IPO Year: | N/A |
| Target Price: | $63.56 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.76 | EPS Growth: | 55.40 |
| 52 Week Low/High: | $42.01 - $70.50 | Next Earning Date: | 08-05-2025 |
| Revenue: | $1,084,306,000 | Revenue Growth: | 25.64% |
| Revenue Growth (this year): | 25.77% | Revenue Growth (next year): | 18.01% |
Stock Insider Trading Activity of Halozyme Therapeutics Inc. (HALO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Torley Helen | HALO | PRESIDENT AND CEO | Jun 20 '25 | Sell | $53.14 | 60,000 | $3,185,279.82 | 733,719 | |
| Henderson Jeffrey William | HALO | Director | Apr 28 '25 | Sell | $60.67 | 4,497 | $271,467.09 | 28,811 |
Latest Halozyme Therapeutics Inc. News
HALO Breaking Stock News: Dive into HALO Ticker-Specific Updates for Smart Investing
Argus Research
11 days ago
HALO: Raising target price to $59.00
PR Newswire
15 days ago
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Zacks
18 days ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Zacks
19 days ago
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
Zacks
22 days ago
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Zacks
23 days ago
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
Argus Research
25 days ago
HALO: What does Argus have to say about HALO?
Zacks
a month ago
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?
Compare HALO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HALO Halozyme Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.